Saudi Tibbiyah forms JV with BGI Almanahil to offer genetic testing services


The signing ceremony among BGI Almanahil and Tibbiyah

Arabian International Healthcare Holding Company (“Tibbiyah”), a leading integrated healthcare solutions provider in Saudi Arabia, today announced a definitive Joint Venture Agreement with BGI Almanahil Health for Medical Services, a subsidiary company of BGI Health (HK) Co., Ltd, in the formation and operation of a limited liability company to be called Saudi Advanced Medical Lab LIMITED (“SAMLL”) in Saudi Arabia. 

The new company, owned 50% by BGI Almanahil and 50% by Tibbiyah, will provide clinical laboratory testing and bio-information services to hospitals, research institutes, and medical centers and clinics for both public and private sectors. 

The CEO of Al Faisaliah Group, Mr. Ziad Al Tunisi, said at the signing ceremony on July 26, “We are delighted to announce this signing of Tibbiyah- BGI Almanahil Joint venture Agreement and believe it will strengthen Tibbiyah’s position as a strong player in the underserved highly specialized clinical laboratory testing KSA healthcare market and reinforce its status as a leading diversified healthcare company.”

CEO of Al Faisaliah Group Mr. Ziad Al Tunisi (left) and Tibbiyah’s CEO Mr. Alaa Ahmed Amee (right)

“This partnership combines the expertise and experience of two high-quality Healthcare providers, creating new opportunities to further develop and expand our healthcare services in the Kingdom, and delivers Tibbiyah strategy to enter into attractive healthcare market segments that have strong fundamentals conducive to growth and as one of the main players in the Kingdom Healthcare Sector,” Mr. Ziad Al Tunisi said.

The CEO of BGI Genomics, Mr. Zhao Lijian said, “With the advantages of both parties, I believe that SAMLL will become the most advanced and competitive independent clinical laboratory, which will better serve the patients and clients, maintain the highest quality standards, continuously introduce new clinical testing services and medical technology to the Kingdom Healthcare Sector.”

CEO of BGI Genomics Mr. Zhao Lijian (second from the right)

About BGI Genomics 

BGI Genomicsheadquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. Our services cover more than 100 countries and regions, involving more than 2,300 medical institutions. In July of 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.